European Non-Invasive Prenatal Testing (NIPT) Opportunities
- How effective are e-commerce and direct-to-customer sales models for growth?
- What partnerships and joint ventures can strengthen your future growth pipeline?
- What impact do artificial intelligence and next-generation sequencing have on the European NIPT industry?
Is Your Team Harnessing Medical Technology's Potential?
- Align your offerings with the growth of minimally invasive surgery techniques.
- Capture opportunities from the rise of at-home care services and technologies.
- Strengthen product innovation and technology-driven disease diagnosis to drive growth.
Key Megatrends Transforming the Heart Valves Industry
- What growth opportunities exist in the Asia-Pacific region?
- Who are the top players, and how do their strategies differ from yours?
- Is your team developing transcatheter mitral and tricuspid valve technologies to achieve growth?
Contract Research Organizations
Who are the key contributors to the drug development pipeline? What is your team’s global position?
Digital Health Regulations
What innovative business models and technologies can your team capitalize on for transformational growth?
Home Care Digitalization
How strong are your remote patient monitoring and smart medication systems to match industry dynamics?
Blood Group Typing Industry
Foster strategic partnerships and alliances that are transformational for your business and trigger growth.
Healthcare Data Interoperability
Maximize the potential of dynamic artificial intelligence for a transformational future.
Oral Solid Dosage Formulation
Leverage personalized medicine and drug delivery technologies enhance to growth potential.
Single Cell Genomics and Proteomics
How does your team align to harness growth from niche technologies?
Biotechnology Investments
What data source and definition variations should your team consider to achieve growth?
Which Growth Opportunities Are Reshaping the Precision Oncology Landscape?
The precision oncology landscape is evolving with technologies like artificial intelligence (AI), machine learning (ML), robotics, and big data-driven multi-omics tools, advancing targeted treatments. Experts, including oncologists, decision-support scientists, and healthcare professionals, are currently navigating the complex process of identifying biomarker correlations based on a patient’s genetic makeup.
Transforming Chronic Care: Prioritizing Patient-Centered Models for Enhanced Outcomes
Patient-centered care, as defined by the National Quality Forum, emphasizes collaborative partnerships among patients, their families, and healthcare providers. It prioritizes individuals’ priorities, goals, needs, and values for better health outcomes.
Despite initial challenges, advancements in remote monitoring devices, wearables, and telehealth technologies are accelerating the shift toward out-of-hospital care models. These innovations are empowering patients, enhancing autonomy, and facilitating seamless collaboration between patients and healthcare providers.
Growth Perspectives: Key Highlights from DCAT 2024
The Drug, Chemical & Associated Technologies Association (DCAT) 2024 event held in New York City showcased product and technology innovations and capabilities presentations by member companies. Industry participants highlighted capability expansion, recent developments, and breakthroughs in pharmaceutical development and manufacturing to support drug development.
Growth Perspectives: Key Highlights from HIMSS 2024 Summit in Orlando
Frost & Sullivan’s experts had the privilege of covering the latest developments at the HIMSS Global Health Conference & Exhibition 2024 in Orlando. Explore the key developments in artificial intelligence (AI), cybersecurity, interoperability and health data sharing, ambient AI scribing, hybrid Care (virtual care, telehealth, remote patient monitoring), and hospital-at-home programs, platforms, and patient engagement.
Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the Fourth Consecutive Year
Frost & Sullivan analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry.
Based on its findings, Subang Jaya Medical Centre (SJMC) is recognized with the 2024 Malaysian Best Hospital Company of the Year Award for the fourth consecutive year in the hospitals industry, making it the first to be recognized continuously with this prestigious accolade.
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology
Frost & Sullivan analyzed the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award.
HUB is a global leader in patient-derived organoid (PDO) technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system.
iSono Health Applauded by Frost & Sullivan for Ensuring Patient Comfort and Safety and Providing Quality Imaging and Diagnosis with Its iSono Health ATUSA
Frost & Sullivan assessed the breast ultrasound industry and based on its findings, recognizes iSono Health with the 2023 United States New Product Innovation Award. The company is carving a new category for the automated breast ultrasound (ABUS) space.
The iSono Health ABUS ATUSA is approved by the US Food and Drug Administration (FDA) and is the world’s first automated, portable, and wearable three-dimensional (3D) breast ultrasound.
Nutrition and Wellness
Growth Opportunities in Nutrition and Wellness Ingredients: How Nutrition Businesses Can Meet Evolving Women's Health Needs
Jun 20th, 2024 10:30 AM EDT
Precision Health
Strategic Positioning in Precision Health: Industry Players and Competitive Benchmarking in Precision Oncology
On-demand
Growth Processes
Explore the major growth opportunities impacting visions, leadership, product launch and development, investments, finance, manufacturing, mergers and acquisitions, research and development, intellectual property, and more.
June 2024
